Scaled up Microfluidic Screening of Skin Care Ingredients Using Multilayer Skin Spheroids

使用多层皮肤球体扩大皮肤护理成分的微流体筛选

• 批准号: 576239-2022
• 负责人: Kumacheva, EugeniaE
• 金额: $ 6.39万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=748308
• 关键词: Scaled; up; Microfluidic; Screening; Skin

Development of multicomponent skin care products is a time-, labor- and cost-intensive task that begins from the identification of a promising individual active ingredient (AI) and continues to the optimization of formulations by using animal models. Experiments on animal models are expensive, time-consuming, and require special skills. Furthermore, due to the ethical considerations, the use of animal models for testing cosmetic ingredients is banned by many countries, including Canadian S-214 "The Cruelty Free Cosmetics Act" that prohibits the sale of cosmetics tried on animals. Therefore, the utilization of reliable in vitro skin models such as multicellular spheroids/organoids is highly recommended and favored. Over the past two years, in collaboration with BASF Corporation, the PI group has designed and developed a microfluidic (MF) platform to grow massive arrays of skin spheroids from human dermal fibroblasts. In the case study, the utility of this MF platform was demonstrated for high-throughput screening of the effect of vitamin C on protein production by fibroblast spheroids. The current one-year proposed research project aims at (i) extending this simplistic skin model by replacing of fibroblast spheroids with fibroblast-keratinocyte spheroids to better replicate an epidermal/dermal skin structure and (ii) designing and developing a new mode of operation of the MF platform that would enable scaled up user-friendly throughput screening of multiple AIs and their combinations. The development of this skin spheroid-on-a-chip platform is a vital step toward time-, cost- and labor-effective manufacturing in the cosmetic and skin care fields, with a potential application in the area of pharmaceuticals, which are of strategic importance for Canada.

多成分护肤品的开发是一项时间、劳动力和成本密集型的任务，从确定一种有前途的单个活性成分（AI）开始，并通过使用动物模型继续优化配方。在动物模型上进行实验既昂贵又耗时，而且需要特殊技能。此外，出于道德考虑，许多国家都禁止使用动物模型来测试化妆品成分，包括加拿大S-214“残忍无化妆品法案”，禁止在动物身上试验的化妆品销售。因此，使用可靠的体外皮肤模型，如多细胞球体/类器官，是非常值得推荐和青睐的。在过去的两年中，PI小组与巴斯夫公司合作，设计并开发了一种微流体（MF）平台，用于从人类真皮成纤维细胞中培养大量皮肤球体阵列。在案例研究中，该MF平台被证明用于高通量筛选维生素C对成纤维细胞球体蛋白生产的影响。目前为期一年的拟议研究项目旨在(i)通过用成纤维细胞-角化细胞球体代替成纤维细胞球体来扩展这种简单的皮肤模型，以更好地复制表皮/真皮皮肤结构；（ii）设计和开发一种新的MF平台操作模式，从而能够扩大对多种ai及其组合的用户友好吞吐量筛选。这种皮肤球体芯片平台的开发是化妆品和皮肤护理领域向时间、成本和劳动力有效的制造迈出的重要一步，在制药领域有潜在的应用，这对加拿大具有战略意义。